We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Close the gap

9 March 2006 By Robert Cyran

The Irish biotech s shares rose 26% after US regulators allowed Tysabri, its drug for multiple sclerosis, back on the market. This has opened up a wide valuation gap between Elan and the company that comarkets the drug Biogen Idec.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)